| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparative study of voluntary deep inspiration breath hold versus free breathing techniques in adjuvant left breast hypofractionated radiotherapy
|
Elkhouly, E.A.
|
|
|
30 |
S3 |
p. iii33
|
artikel
|
| 2 |
A cost-utility analysis of administration schedules of G-CSF for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer: Economic evaluation alongside the REaCT-G trial
|
Basulaiman, B.
|
|
|
30 |
S3 |
p. iii68
|
artikel
|
| 3 |
Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients
|
Martín, M.
|
|
|
30 |
S3 |
p. iii17
|
artikel
|
| 4 |
Adherence to dietary guidelines (DG) and body weight change (BWC) in early-stage breast cancer (EBC): A prospective trial in patients submitted to nutrition evidence-based educational intervention
|
Carbognin, L.
|
|
|
30 |
S3 |
p. iii66
|
artikel
|
| 5 |
Adjuvant management of male breast cancer in Bulgaria
|
Konsoulova-Kirova, A.A.
|
|
|
30 |
S3 |
p. iii31
|
artikel
|
| 6 |
Adjuvant radiotherapy induces secondary tumor events in breast cancer patients with Li-Fraumeni syndrome
|
Rounis, K.
|
|
|
30 |
S3 |
p. iii30
|
artikel
|
| 7 |
Adjuvant trastuzumab in stage I breast cancer with the tumour size < 1cm: Our centre experience
|
Belikova, H.
|
|
|
30 |
S3 |
p. iii30
|
artikel
|
| 8 |
A four-year study of epidemiological trends of breast cancer in a Haitian cancer program
|
Bernard, J.J.
|
|
|
30 |
S3 |
p. iii56
|
artikel
|
| 9 |
After breast cancer: A nurse practitioner led model of care for women on adjuvant endocrine treatment
|
Shenkier, T.
|
|
|
30 |
S3 |
p. iii67
|
artikel
|
| 10 |
A nationwide, multi-institutional retrospective study of efficacy and safety of eribulin in Korean breast cancer patients (REMARK)
|
Jeong, J.
|
|
|
30 |
S3 |
p. iii58
|
artikel
|
| 11 |
An in vivo genome-wide RNAi screen identifies novel mediators of paclitaxel response in breast cancer
|
Sultan, M.
|
|
|
30 |
S3 |
p. iii23-iii24
|
artikel
|
| 12 |
A nomogram for predicting the malignant diagnosis of BI-RADS US category 4A lesions in women with dense breast tissue
|
Yang, Y.
|
|
|
30 |
S3 |
p. iii42
|
artikel
|
| 13 |
A nomogram integrating reverse phase protein array based proteomic signature and clinical variables improves prognostic prediction in non-metastatic breast cancer after surgery
|
Junping, Y.
|
|
|
30 |
S3 |
p. iii8
|
artikel
|
| 14 |
Anti HER-2 therapies and left ventricular dysfunction: A prospective study
|
Daniele, A.J.
|
|
|
30 |
S3 |
p. iii32
|
artikel
|
| 15 |
Anti-inflammatory treatment and inhibition of B-cell activation in a nude mouse model of human breast cancer
|
Fernandez Madrid, F.
|
|
|
30 |
S3 |
p. iii20
|
artikel
|
| 16 |
A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases
|
Clemons, M.
|
|
|
30 |
S3 |
p. iii73
|
artikel
|
| 17 |
A prospective comparative study of sentinel lymph node biopsy with indo-cyanine green (ICG) florescence technique versus dual dye technique for early breast cancer: Going beyond the horizon
|
Kr, A.
|
|
|
30 |
S3 |
p. iii41-iii42
|
artikel
|
| 18 |
A prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer
|
Awan, A.A.
|
|
|
30 |
S3 |
p. iii66-iii67
|
artikel
|
| 19 |
A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)
|
Paplomata, E.
|
|
|
30 |
S3 |
p. iii63-iii64
|
artikel
|
| 20 |
Are single hormone receptor-positive phenotypes biologically and clinically distinct breast cancer? A population-based study
|
Li, Y.
|
|
|
30 |
S3 |
p. iii6
|
artikel
|
| 21 |
Association of serum IGF1 and adiponectin in prognosis of breast cancer metastasis
|
Akter, S.
|
|
|
30 |
S3 |
p. iii54
|
artikel
|
| 22 |
A systematic review of endocrine deprivation therapy administered in the neoadjuvant setting in double positive breast cancer
|
Smith, M.A.
|
|
|
30 |
S3 |
p. iii37
|
artikel
|
| 23 |
A systemic review of information requirements of young women with breast cancer undergoing mastectomy or breast conserving surgery
|
Mehmood, T.
|
|
|
30 |
S3 |
p. iii44
|
artikel
|
| 24 |
Biological features of estrogen receptor-positive breast cancer with elevated RANK (TNFRSF11A) expression
|
Casimiro, S.
|
|
|
30 |
S3 |
p. iii9
|
artikel
|
| 25 |
Bone seeking matrix metalloproteinase-2 (MMP-2) inhibitors can prevent bone metastatic breast cancer
|
Tauro, M.
|
|
|
30 |
S3 |
p. iii60-iii61
|
artikel
|
| 26 |
Brain metastasis of breast cancer: A 10-year single institution retrospective analysis
|
Batista, M. Vaz
|
|
|
30 |
S3 |
p. iii56
|
artikel
|
| 27 |
Brazilian randomized study: Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery (BREAST-MRI Trial)
|
Mota, B.S.
|
|
|
30 |
S3 |
p. iii39-iii40
|
artikel
|
| 28 |
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience
|
Molinaro, E.
|
|
|
30 |
S3 |
p. iii15
|
artikel
|
| 29 |
BRCA status, treatment patterns and outcomes in HER2- advanced breast cancer (ABC): A multi-country real-world study
|
Niyazov, A.
|
|
|
30 |
S3 |
p. iii51-iii52
|
artikel
|
| 30 |
Breast cancer early recurrences in young women
|
Cima, S.
|
|
|
30 |
S3 |
p. iii32
|
artikel
|
| 31 |
Breast cancer in young women: A multi-center 10-year experience
|
Eiriz, I.F.
|
|
|
30 |
S3 |
p. iii32
|
artikel
|
| 32 |
Breast cancer specific graded prognostic assessment (BC-GPA) score and outcome of HER 2 positive breast cancer patients with brain metastases: A single centre retrospective analysis
|
Kate, S.
|
|
|
30 |
S3 |
p. iii55
|
artikel
|
| 33 |
CAM-H2 effectively targets and treats HER2 positive brain lesions: A comparative preclinical study with trastuzumab
|
Puttemans, J.
|
|
|
30 |
S3 |
p. iii59
|
artikel
|
| 34 |
Can sentinel node biopsy be considered in early breast cancer with axillary nodal disease?
|
May-Miller, P.
|
|
|
30 |
S3 |
p. iii43
|
artikel
|
| 35 |
CDK 4/6 inhibitors plus endocrine therapy in ER positive metastatic breast cancer (MBC): Systematic review and meta-analysis of randomized clinical trials
|
D’Avanzo, F.
|
|
|
30 |
S3 |
p. iii51
|
artikel
|
| 36 |
CD146 suppresses breast tumor via its novel downstream signaling pathway, Latexin/Akt/NFκB
|
Ouhtit, A.
|
|
|
30 |
S3 |
p. iii59
|
artikel
|
| 37 |
Characteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatment
|
Bos, M.K.
|
|
|
30 |
S3 |
p. iii7
|
artikel
|
| 38 |
Cholesterol-lowering medication: Impact on the clinical effect of adjuvant endocrine treatment in postmenopausal breast cancer
|
Harborg, K.S.
|
|
|
30 |
S3 |
p. iii29-iii30
|
artikel
|
| 39 |
CIP2A as a novel target to combat basal like breast cancer
|
Nagelli, S.
|
|
|
30 |
S3 |
p. iii14-iii15
|
artikel
|
| 40 |
Circulating tumor DNA and disease recurrence in early stage breast cancer: From a case-control study to a prospective longitudinal trial
|
Di Cosimo, S.
|
|
|
30 |
S3 |
p. iii28-iii29
|
artikel
|
| 41 |
Clinical, biological and histological features predictive of response to everolimus in metastatic breast cancer patients
|
Van den bossche, V.
|
|
|
30 |
S3 |
p. iii59-iii60
|
artikel
|
| 42 |
Clinical outcome of early stage breast cancer patients with 1 to 3 positive axillary lymph nodes: A single institution experience
|
Arjunan, A.
|
|
|
30 |
S3 |
p. iii40
|
artikel
|
| 43 |
Clinical significance of BCL-2 with basal and non-basal triple negative breast cancer (TNBC)
|
Srinivasalu, V.K.
|
|
|
30 |
S3 |
p. iii46
|
artikel
|
| 44 |
Clinico-pathological relationship between androgen receptor (AR) and tumor infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC)
|
Elghazawy, H.
|
|
|
30 |
S3 |
p. iii22-iii23
|
artikel
|
| 45 |
Comparison of breast cancer outcomes in a private hospital with national outcomes in a country with a mixed public/private healthcare model
|
Killian, M.
|
|
|
30 |
S3 |
p. iii68
|
artikel
|
| 46 |
Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 159 breast cancer patients - indicating tumoral heterogeneity
|
Weydandt, L.
|
|
|
30 |
S3 |
p. iii12
|
artikel
|
| 47 |
Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)
|
Scott, M.
|
|
|
30 |
S3 |
p. iii4
|
artikel
|
| 48 |
Comprehensive evaluation of methodology to assess abundance of immune infiltrates in breast cancer
|
Nederlof, I.
|
|
|
30 |
S3 |
p. iii2
|
artikel
|
| 49 |
Compromised cancer-specific survival among under-insured Chinese patients with breast cancer: A prospective cohort study
|
Xie, Y.
|
|
|
30 |
S3 |
p. iii68
|
artikel
|
| 50 |
Controlling nutritional status (CONUT) score is a prognostic factor in patients with resected breast cancer
|
Li, W.
|
|
|
30 |
S3 |
p. iii20
|
artikel
|
| 51 |
Current treatment landscape in triple negative breast cancer: A systematic literature review
|
Fu, A.Z.
|
|
|
30 |
S3 |
p. iii55-iii56
|
artikel
|
| 52 |
3D association of ER, PR and HER2 to aid sub-grouping of breast cancer patients
|
Zhang, J.
|
|
|
30 |
S3 |
p. iii15
|
artikel
|
| 53 |
Decisions for immediate breast reconstruction: Do surgeons make sensible choices?
|
Zaidi, M.
|
|
|
30 |
S3 |
p. iii43
|
artikel
|
| 54 |
Defining the physiological miRNA landscape in nipple aspirate fluid
|
Patuleia, S.I.S.
|
|
|
30 |
S3 |
p. iii13
|
artikel
|
| 55 |
Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients
|
Haugen, M.H.
|
|
|
30 |
S3 |
p. iii8
|
artikel
|
| 56 |
Differences between breast cancer subtypes in developing metastatic disease
|
Wildiers, H.
|
|
|
30 |
S3 |
p. iii50
|
artikel
|
| 57 |
Differential regulation of glucocorticoid receptor signaling in luminal, triple negative and HER2+ breast cancer cells
|
Zhidkova, E.
|
|
|
30 |
S3 |
p. iii21-iii22
|
artikel
|
| 58 |
DNA methylation markers of breast cancer response to anthracycline based neoadjuvant chemotherapy
|
Sigin, V.O.
|
|
|
30 |
S3 |
p. iii24
|
artikel
|
| 59 |
Dose-dense adjuvant chemotherapy in early breast cancer: 15–year results of the phase III Mammella InterGruppo (MIG)-1 study
|
Blondeaux, E.
|
|
|
30 |
S3 |
p. iii27
|
artikel
|
| 60 |
Dose dense neoadjuvant and adjuvant chemotherapy in triple-negative breast cancer patients: Survival analysis
|
Kr, A.
|
|
|
30 |
S3 |
p. iii37
|
artikel
|
| 61 |
Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
|
Vasan, N.
|
|
|
30 |
S3 |
p. iii1
|
artikel
|
| 62 |
Downregulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in breast cancer: A new insight into the mechanism of induction of antitumor immunity
|
Sadighi, S.
|
|
|
30 |
S3 |
p. iii12
|
artikel
|
| 63 |
Drug Index
|
|
|
|
30 |
S3 |
p. iii74
|
artikel
|
| 64 |
Dual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC)
|
Zoi, I.
|
|
|
30 |
S3 |
p. iii21
|
artikel
|
| 65 |
Ductal carcinoma in situ of the breast: Immune cell composition according to subtype
|
Agahozo, M.C.
|
|
|
30 |
S3 |
p. iii5
|
artikel
|
| 66 |
Dynamic monitoring of ctDNA reveals that acquired NF2 mutations confer resistance to HER2 targeted therapy in HER2-mutant breast cancer
|
Li, X.
|
|
|
30 |
S3 |
p. iii5
|
artikel
|
| 67 |
Early prediction of non-pCR using ultrasound-guided serial core needle biopsy in HER2-positive breast cancer patients
|
Zhang, Y.
|
|
|
30 |
S3 |
p. iii34
|
artikel
|
| 68 |
Editorial board
|
|
|
|
30 |
S3 |
p. ii-iii
|
artikel
|
| 69 |
Efficacy and tolerability of neratinib in advanced HER-2 positive breast cancer: A single institution experience
|
Shepherd, S.T.C.
|
|
|
30 |
S3 |
p. iii59
|
artikel
|
| 70 |
Efficacy of trastuzumab-emtansina (T-DM1) in HER2-positive breast cancer (BC) with brain metastases (BM): A single institution experience
|
Martin Huertas, R.
|
|
|
30 |
S3 |
p. iii60
|
artikel
|
| 71 |
Efficacy of using imprint and exfoliative cytology followed by frozen section as intraoperative margin assessment in breast conservation surgery
|
Tamanuki, T.
|
|
|
30 |
S3 |
p. iii43
|
artikel
|
| 72 |
Endocrine implications in male breast cancer in Bulgaria
|
Konsoulova-Kirova, A.A.
|
|
|
30 |
S3 |
p. iii12-iii13
|
artikel
|
| 73 |
ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)
|
Griguolo, G.
|
|
|
30 |
S3 |
p. iii7
|
artikel
|
| 74 |
ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy
|
Keizer, D.
|
|
|
30 |
S3 |
p. iii16
|
artikel
|
| 75 |
ESR1 mutations are similarly prevalent in newly metastatic and loco-regional recurrence of endocrine-treated breast cancer patients and carry worse prognosis
|
Nili Gal Yam, E.
|
|
|
30 |
S3 |
p. iii8
|
artikel
|
| 76 |
Evaluation of intraoperative frozen section with final histopathology results for sentinel lymph node biopsy in breast cancer
|
Kr, A.
|
|
|
30 |
S3 |
p. iii44
|
artikel
|
| 77 |
Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy
|
Huang, M.
|
|
|
30 |
S3 |
p. iii34-iii35
|
artikel
|
| 78 |
Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial
|
Guarneri, V.
|
|
|
30 |
S3 |
p. iii73
|
artikel
|
| 79 |
Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)
|
Denkert, C.
|
|
|
30 |
S3 |
p. iii8-iii9
|
artikel
|
| 80 |
Expression of immunomodulatory molecule, programmed death ligand-1 in triple negative invasive breast cancer in the Indian population
|
Gorijavolu, N.B.
|
|
|
30 |
S3 |
p. iii45
|
artikel
|
| 81 |
Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: Pooled analysis based on the GBG database
|
Huober, J.
|
|
|
30 |
S3 |
p. iii34
|
artikel
|
| 82 |
Feasibility of a self-screening for insomnia and acceptability of an online targeted video-based cognitive behavioral program in cancer outpatients: SLEEP-4-ALL-1 study design
|
Charles, C.
|
|
|
30 |
S3 |
p. iii71
|
artikel
|
| 83 |
Feasibility of quantitative sensory testing (QST) in clinical routine as a tool to evaluate chemotherapy-induced peripheral neuropathy (CIPN) amongst breast cancer patients treated with taxanes
|
Ioannou, I.
|
|
|
30 |
S3 |
p. iii70-iii71
|
artikel
|
| 84 |
Feasibility study of using an app-based mHealth group challenge to improve physical activity (PA) and fatigue after breast cancer (BC)
|
Martin, E.
|
|
|
30 |
S3 |
p. iii71
|
artikel
|
| 85 |
Final results of scalp cooling for hair preservation: A single-institution prospective study
|
Loparco, D.
|
|
|
30 |
S3 |
p. iii32-iii33
|
artikel
|
| 86 |
First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)
|
Aftimos, P.G.
|
|
|
30 |
S3 |
p. iii48
|
artikel
|
| 87 |
Founder mutations BRCA2 c.156_157insAlu in Portuguese population
|
Macedo, F.
|
|
|
30 |
S3 |
p. iii20
|
artikel
|
| 88 |
Functional CRISPR knockout screens for modifiers of sensitivity to trastuzumab emtansine
|
Lipert, B.
|
|
|
30 |
S3 |
p. iii22
|
artikel
|
| 89 |
Gastrointestinal symptoms & health-related quality of life among women with HR+/HER2– advanced or metastatic breast cancer treated in real-world settings in Italy and Germany
|
Brucker, S.
|
|
|
30 |
S3 |
p. iii55
|
artikel
|
| 90 |
GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo
|
Loibl, S.
|
|
|
30 |
S3 |
p. iii38
|
artikel
|
| 91 |
Germline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm
|
Ouyang, Q.
|
|
|
30 |
S3 |
p. iii11-iii12
|
artikel
|
| 92 |
Growth inhibition of triple-negative breast cancer cells due to the lack of CD73
|
Petruk, N.
|
|
|
30 |
S3 |
p. iii20
|
artikel
|
| 93 |
Hep par 1 immunohistochemistry in glycogen-rich clear cell carcinoma of the breast
|
Chang, M.C.
|
|
|
30 |
S3 |
p. iii23
|
artikel
|
| 94 |
Hereditary breast and ovarian cancer syndrome: Descriptive analysis of a familial cancer clinic
|
Amaral, S.R.
|
|
|
30 |
S3 |
p. iii16
|
artikel
|
| 95 |
HER2-positive breast cancer and CNS metastases: Prognostic factors and clinical outcome
|
Agostinetto, E.
|
|
|
30 |
S3 |
p. iii60
|
artikel
|
| 96 |
HER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib
|
Tomasevic, Z.
|
|
|
30 |
S3 |
p. iii25
|
artikel
|
| 97 |
HER2-targeted antibody dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells against tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines
|
Collins, D.M.
|
|
|
30 |
S3 |
p. iii18
|
artikel
|
| 98 |
Heterozygous mutation in fanconi anemia genes associated with hereditary breast cancer
|
Gordiev, M.
|
|
|
30 |
S3 |
p. iii10
|
artikel
|
| 99 |
Higher ER load is not associated with better outcome in stage I-III breast cancer
|
Noordhoek, I.
|
|
|
30 |
S3 |
p. iii16-iii17
|
artikel
|
| 100 |
HIV infection in breast cancer patients from Mozambique: A prospective cohort study
|
Brandão, M.D.R.A.
|
|
|
30 |
S3 |
p. iii69
|
artikel
|
| 101 |
Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA
|
Ettl, J.
|
|
|
30 |
S3 |
p. iii52
|
artikel
|
| 102 |
Identification of serum proteome signatures of male breast cancer
|
Zografos, E.
|
|
|
30 |
S3 |
p. iii21
|
artikel
|
| 103 |
Imaging-proven venous thromboembolism among breast cancer patients in a tertiary hospital in the Philippines from 2010-2015
|
Gerona, A.T.B.
|
|
|
30 |
S3 |
p. iii61
|
artikel
|
| 104 |
Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling
|
Vos, H.
|
|
|
30 |
S3 |
p. iii45
|
artikel
|
| 105 |
Immune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer
|
Langouo Fontsa, M.
|
|
|
30 |
S3 |
p. iii45
|
artikel
|
| 106 |
Impact of BRCA1/2 mutations status on patient reported outcomes in HER2- advanced breast cancer: Results from a multi-country real-world study
|
Rider, A.
|
|
|
30 |
S3 |
p. iii54-iii55
|
artikel
|
| 107 |
Impact of delayed adjuvant chemotherapy: The Royal Marsden Hospital (RMH) experience
|
Okines, A.F.C.
|
|
|
30 |
S3 |
p. iii28
|
artikel
|
| 108 |
Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial
|
Fasching, P.A.
|
|
|
30 |
S3 |
p. iii49
|
artikel
|
| 109 |
Impact of older age on the locoregional and distant breast cancer recurrence risk: A large population-based study
|
de Boer, A.Z.
|
|
|
30 |
S3 |
p. iii27
|
artikel
|
| 110 |
Impact of tamoxifen (TAM) serum concentration on side effects among premenopausal patients (pts) with early breast cancer (BC) in the prospective multicenter CANTO cohort
|
Ferreira, A.R.
|
|
|
30 |
S3 |
p. iii29
|
artikel
|
| 111 |
Impact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: Results of the KARMA Dx study
|
Llombart, A.
|
|
|
30 |
S3 |
p. iii9-iii10
|
artikel
|
| 112 |
Implant-based breast cancer reconstruction with biological matric or synthetic mesh
|
Sukhotko, A.
|
|
|
30 |
S3 |
p. iii44
|
artikel
|
| 113 |
Improved survival of young patients with breast cancer ≤ 40 years of age at diagnosis
|
El Dick, J.
|
|
|
30 |
S3 |
p. iii31
|
artikel
|
| 114 |
Increased risk of breast cancer-specific mortality among women with second primary breast cancer: A SEER population-based study
|
Wang, C.
|
|
|
30 |
S3 |
p. iii66
|
artikel
|
| 115 |
Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity
|
Rypens, C.
|
|
|
30 |
S3 |
p. iii23
|
artikel
|
| 116 |
Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials
|
Jank, P.
|
|
|
30 |
S3 |
p. iii6
|
artikel
|
| 117 |
Influence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer
|
Claessens, A.K.M.
|
|
|
30 |
S3 |
p. iii51
|
artikel
|
| 118 |
Inotilone interferes with chromosome replication as an attractive anti-cancer drug target for breast cancer
|
Chen, L.-C.
|
|
|
30 |
S3 |
p. iii24
|
artikel
|
| 119 |
Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02)
|
Erdkamp, F.L.G.
|
|
|
30 |
S3 |
p. iii50-iii51
|
artikel
|
| 120 |
Intrahepatic mitomycin C infusion in breast cancer liver metastases
|
Aarts, B.
|
|
|
30 |
S3 |
p. iii57-iii58
|
artikel
|
| 121 |
Intraoperative radiotherapy with electronic brachytherapy system in breast cancer patients: Systematic review
|
Vasileva, M.B.
|
|
|
30 |
S3 |
p. iii41
|
artikel
|
| 122 |
Investigation on the MyD88 mediated TLR3 signaling via cell surface in breast cancer
|
Singh, A.
|
|
|
30 |
S3 |
p. iii46
|
artikel
|
| 123 |
KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)
|
Cardoso, F.
|
|
|
30 |
S3 |
p. iii38
|
artikel
|
| 124 |
Late-term effects in the arm and shoulder with hypofractionated regional nodal irradiation in patients with breast cancer
|
Yadav, B.S.
|
|
|
30 |
S3 |
p. iii39
|
artikel
|
| 125 |
Locoregional therapy targeted at the primary tumour improves overall survival in patients with stage IV metastatic breast cancer: A systematic review and meta-analysis with 185942 patients
|
Gera, R.
|
|
|
30 |
S3 |
p. iii52-iii53
|
artikel
|
| 126 |
Long duration of breastfeeding is associated to inflammatory breast (IBC) cancer
|
Mejri, N.
|
|
|
30 |
S3 |
p. iii22
|
artikel
|
| 127 |
Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
|
Guan, X.
|
|
|
30 |
S3 |
p. iii6
|
artikel
|
| 128 |
Long non-coding RNA PART1 contributes to cell proliferation and stem cell maintenance in triple-negative breast cancer
|
Cruickshank, B.M.
|
|
|
30 |
S3 |
p. iii22
|
artikel
|
| 129 |
Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial
|
Eiger, D.
|
|
|
30 |
S3 |
p. iii65
|
artikel
|
| 130 |
Male breast cancer, a heterogeneous entity: Experience from a cancer center
|
Carvalho, J.C.
|
|
|
30 |
S3 |
p. iii69-iii70
|
artikel
|
| 131 |
Mammographic density change and risk of breast cancer
|
Azam, S.
|
|
|
30 |
S3 |
p. iii4-iii5
|
artikel
|
| 132 |
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
|
Svartdal, L.G.
|
|
|
30 |
S3 |
p. iii11
|
artikel
|
| 133 |
miR-210 and miR-152 as biomarkers in invasive ductal carcinoma by liquid biopsy
|
Zuccari, D.A.P.D.C.
|
|
|
30 |
S3 |
p. iii21
|
artikel
|
| 134 |
miRNA expression profiles in BRCA1-associated breast cancers reveal upregulation of specific miRNAs in tumors lacking a clear second hit in a large proportion of the tumour
|
Van Heetvelde, M.
|
|
|
30 |
S3 |
p. iii72
|
artikel
|
| 135 |
Molecular sub types of breast cancer in a developing country. Classification immunohistochemical: Clinicopathologic feature and survival analysis
|
Castro, H.R.
|
|
|
30 |
S3 |
p. iii33
|
artikel
|
| 136 |
Multi-gene panel testing at the hereditary breast and ovarian cancer (HBOC) unit of the Hospital Clinic of Barcelona
|
Adamo, B.
|
|
|
30 |
S3 |
p. iii42-iii43
|
artikel
|
| 137 |
Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients
|
Palazón Carrión, N.
|
|
|
30 |
S3 |
p. iii19
|
artikel
|
| 138 |
Nomogram for predicting axillary lymph node pathological complete response after neoadjuvant chemotherapy in node-positive breast cancer patients
|
Wang, W.
|
|
|
30 |
S3 |
p. iii35
|
artikel
|
| 139 |
Non-invasive and low-cost technique for early detection of clinically relevant breast lesions using a handheld point-of-care medical device (iBreast): Prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries
|
Kr, A.
|
|
|
30 |
S3 |
p. iii65
|
artikel
|
| 140 |
Non-vigorous physical activity and the risk of breast cancer among Nigerian women
|
Azubuike, S.O.
|
|
|
30 |
S3 |
p. iii61
|
artikel
|
| 141 |
Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)
|
Mosele, M.F.
|
|
|
30 |
S3 |
p. iii47
|
artikel
|
| 142 |
Outcomes of women at high familial risk for breast cancer in Australia: An 8-year single-centre experience
|
Lammert, J.
|
|
|
30 |
S3 |
p. iii5
|
artikel
|
| 143 |
Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study
|
Altuna, S.C.
|
|
|
30 |
S3 |
p. iii14
|
artikel
|
| 144 |
Palbociclib in daily clinical use: Real world experience of the breast center at the University Hospital Munich
|
Hester, A.
|
|
|
30 |
S3 |
p. iii58
|
artikel
|
| 145 |
Palbociclib-induced senescence upregulates the expression of IL-8 and may enhance the response to inmunotherapy
|
Martinez Bueno, A.
|
|
|
30 |
S3 |
p. iii15-iii16
|
artikel
|
| 146 |
Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study
|
Welt, A.
|
|
|
30 |
S3 |
p. iii50
|
artikel
|
| 147 |
PALBOCOMP: Retrospective observational analysis of palbociclib treatment in patients with advanced breast cancer within a compassionate use program in Spain
|
Manso, L.
|
|
|
30 |
S3 |
p. iii62
|
artikel
|
| 148 |
PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer
|
Prat, A.
|
|
|
30 |
S3 |
p. iii3
|
artikel
|
| 149 |
Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling
|
Karn, T.
|
|
|
30 |
S3 |
p. iii4
|
artikel
|
| 150 |
Pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes
|
Rapoport, B.L.
|
|
|
30 |
S3 |
p. iii37
|
artikel
|
| 151 |
Pathological complete response rates following neoadjuvant systemic therapy in 300 patients with early or locally advanced HER2 positive breast cancer: The Royal Marsden experience
|
Chaabouni, N.
|
|
|
30 |
S3 |
p. iii36
|
artikel
|
| 152 |
Patient-reported health problems and health care use after treatment for early breast cancer
|
de Ligt, K.M.
|
|
|
30 |
S3 |
p. iii69
|
artikel
|
| 153 |
Perioperative factors and complications after delayed reconstruction in breast cancer patients in relation to outcome
|
Dillekås, H.E.
|
|
|
30 |
S3 |
p. iii41
|
artikel
|
| 154 |
Pertuzumab (P) as ≥ second-line therapy for HER2-positive metastatic breast cancer (mBC): Swiss clinical experience
|
Biskup, E.M.
|
|
|
30 |
S3 |
p. iii57
|
artikel
|
| 155 |
Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)
|
Huober, J.
|
|
|
30 |
S3 |
p. iii47
|
artikel
|
| 156 |
Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for HER2-positive breast cancer
|
Verma, S.
|
|
|
30 |
S3 |
p. iii62
|
artikel
|
| 157 |
Phase III study of [fam-] trastuzumab deruxtecan vs investigator’s choice in T-DM1-pretreated HER2+ breast cancer
|
André, F.
|
|
|
30 |
S3 |
p. iii63
|
artikel
|
| 158 |
Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients
|
Keyaerts, M.
|
|
|
30 |
S3 |
p. iii25-iii26
|
artikel
|
| 159 |
Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)
|
Tripathy, D.
|
|
|
30 |
S3 |
p. iii49-iii50
|
artikel
|
| 160 |
Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)
|
Tripathy, D.
|
|
|
30 |
S3 |
p. iii53
|
artikel
|
| 161 |
Predictive role of derived neutrophil to lymphocyte ratio on platinum-based chemotherapy in triple-negative breast cancer
|
Marra, A.
|
|
|
30 |
S3 |
p. iii61
|
artikel
|
| 162 |
Prevalence of risk factors for QT prolongation and torsades de pointes among women with HR+/HER2– advanced or metastatic breast cancer treated in real-world settings in Italy and Germany
|
Harbeck, N.
|
|
|
30 |
S3 |
p. iii53
|
artikel
|
| 163 |
Preventive bilateral mastectomy (PBS) in BRCA mutation carriers with ovarian cancer: Is it justified?
|
Safra, T.
|
|
|
30 |
S3 |
p. iii65-iii66
|
artikel
|
| 164 |
Prognostic and predictive significance of the expression of the beta-2 adrenergic receptor in HER2-positive breast cancer
|
Richard, F.
|
|
|
30 |
S3 |
p. iii23
|
artikel
|
| 165 |
Prognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab
|
Debska-Szmich, S.
|
|
|
30 |
S3 |
p. iii18
|
artikel
|
| 166 |
Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer
|
Bajaj, R.
|
|
|
30 |
S3 |
p. iii19
|
artikel
|
| 167 |
Prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC)
|
Srinivasalu, V.K.
|
|
|
30 |
S3 |
p. iii14
|
artikel
|
| 168 |
Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials
|
Sestak, I.
|
|
|
30 |
S3 |
p. iii1
|
artikel
|
| 169 |
Prognostic value of Ki-67 in patients with triple-negative breast cancer receiving neo-adjuvant or adjuvant chemotherapy: A systematic review and meta-analysis
|
Zhou, Q.
|
|
|
30 |
S3 |
p. iii15
|
artikel
|
| 170 |
Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients
|
Wuerstlein, R.
|
|
|
30 |
S3 |
p. iii67
|
artikel
|
| 171 |
Rate of breast-conserving surgery vs mastectomy in developing countries
|
Kr, A.
|
|
|
30 |
S3 |
p. iii43-iii44
|
artikel
|
| 172 |
Real world patterns of use and value of pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience
|
Rahardja, S.
|
|
|
30 |
S3 |
p. iii55
|
artikel
|
| 173 |
Regulation of MMP9 expression by human arylamine N-acetyltransferase (NAT1) via Hif-1a
|
Li, P.
|
|
|
30 |
S3 |
p. iii58
|
artikel
|
| 174 |
Relapse after radical subcutaneous mastectomy with simultaneous reconstruction in patients with breast cancer
|
Rasskazova, E.
|
|
|
30 |
S3 |
p. iii44
|
artikel
|
| 175 |
Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial
|
Loi, S.
|
|
|
30 |
S3 |
p. iii2
|
artikel
|
| 176 |
RESCUE: Reaching for evidence-based chemotherapy use in endocrine sensitive breast cancer - A prospective non-interventional study on risk assessment by the endopredict test and long-term patient outcome in early luminal breast cancer
|
Ettl, J.
|
|
|
30 |
S3 |
p. iii25
|
artikel
|
| 177 |
Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial
|
Loibl, S.
|
|
|
30 |
S3 |
p. iii48-iii49
|
artikel
|
| 178 |
RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer
|
Liefaard, M.C.
|
|
|
30 |
S3 |
p. iii13
|
artikel
|
| 179 |
Role of short-course radiotherapy in post-operative carcinoma of the breast
|
Behera, M.K.
|
|
|
30 |
S3 |
p. iii41
|
artikel
|
| 180 |
Safe chemotherapy for treating early breast cancer in G6PD-deficient patients
|
Donisi, C.
|
|
|
30 |
S3 |
p. iii33
|
artikel
|
| 181 |
SAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer
|
Vetter, M.H.F.
|
|
|
30 |
S3 |
p. iii52
|
artikel
|
| 182 |
SCAN-B-rec: Infrastructure, technology and clinical research platform to profile and monitor metastatic breast cancer
|
Bosch, A.
|
|
|
30 |
S3 |
p. iii25
|
artikel
|
| 183 |
Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target
|
Duso, B.A.
|
|
|
30 |
S3 |
p. iii6-iii7
|
artikel
|
| 184 |
Second malignancies with breast cancer: An audit
|
Srinivasalu, V.K.
|
|
|
30 |
S3 |
p. iii67-iii68
|
artikel
|
| 185 |
Sensitivity and dynamic range of CellSearch based CSF DTC enumeration in patients with breast cancer related leptomeningeal metastases (LM)
|
Van Goethem, A.
|
|
|
30 |
S3 |
p. iii60
|
artikel
|
| 186 |
SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
|
Boni, V.
|
|
|
30 |
S3 |
p. iii63
|
artikel
|
| 187 |
Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial
|
Yonemori, K.
|
|
|
30 |
S3 |
p. iii48
|
artikel
|
| 188 |
Spindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers
|
Gatalica, Z.
|
|
|
30 |
S3 |
p. iii19
|
artikel
|
| 189 |
Study of pathological complete response rates with neoadjuvant concurrent chemoradiation with paclitaxel in locally advanced breast cancer
|
Iyer, P.
|
|
|
30 |
S3 |
p. iii36
|
artikel
|
| 190 |
Subtype-guided 18F-FDG PET/CT in tailoring axillary surgery among node-positive breast cancer patients treated with neoadjuvant chemotherapy: A feasibility study
|
Wu, S.
|
|
|
30 |
S3 |
p. iii35
|
artikel
|
| 191 |
Surgical management of breast cancer in BRCA mutation carriers: A single centre experience
|
Fachinetti, A.
|
|
|
30 |
S3 |
p. iii42
|
artikel
|
| 192 |
SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
|
Maurer, C.
|
|
|
30 |
S3 |
p. iii62
|
artikel
|
| 193 |
Table of Contents
|
|
|
|
30 |
S3 |
p. iv
|
artikel
|
| 194 |
Talking about risk in the context of genomic tests (TARGET): Evaluation of an educational program
|
Jenkin, V.A.
|
|
|
30 |
S3 |
p. iii31
|
artikel
|
| 195 |
The adipokine receptor CAP1 regulates breast cancer cell proliferation
|
Bergqvist, M.
|
|
|
30 |
S3 |
p. iii24
|
artikel
|
| 196 |
The analysis of statistics of breast cancer in Cherkassy region before and after Chernobyl disaster
|
Zrielykh, L.
|
|
|
30 |
S3 |
p. iii66
|
artikel
|
| 197 |
The aromatase inactivator exemestane suppresses serum leptin levels significantly in vivo - in contrast to the aromatase inhibitor letrozole
|
Bahrami, N.
|
|
|
30 |
S3 |
p. iii35
|
artikel
|
| 198 |
The changing role of gene-expression profiling in the era of de-escalating adjuvant chemotherapy in early stage breast cancer
|
Steenhoven, J.V.
|
|
|
30 |
S3 |
p. iii30
|
artikel
|
| 199 |
The clinical impact of substituting multigene assays: Comparative clinical analysis of PAM50-ROR versus 21-gene assay
|
Markopoulos, C.J.
|
|
|
30 |
S3 |
p. iii7
|
artikel
|
| 200 |
The early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC
|
Sirico, M.M.
|
|
|
30 |
S3 |
p. iii17
|
artikel
|
| 201 |
The incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer
|
Broadbent, R.
|
|
|
30 |
S3 |
p. iii35-iii36
|
artikel
|
| 202 |
The metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms
|
Lessi, F.
|
|
|
30 |
S3 |
p. iii16
|
artikel
|
| 203 |
The mutational profile of IBC reveals higher mutational burden, deficiency of homologous recombination and NOTCH signalling
|
Van Laere, S.J.
|
|
|
30 |
S3 |
p. iii4
|
artikel
|
| 204 |
The negative pressure therapy with PICO as a prevention of surgical site infection in high risk patients undergoing breast surgery
|
Fogacci, T.
|
|
|
30 |
S3 |
p. iii42
|
artikel
|
| 205 |
The outcome of patients with metastatic breast cancer with lung metastasis treated with fulvestrant is superior to that of those with liver metastasis
|
He, M.
|
|
|
30 |
S3 |
p. iii56
|
artikel
|
| 206 |
The predictive value of NHS PREDICT for triple negative breast cancer
|
Sobočan, M.
|
|
|
30 |
S3 |
p. iii70
|
artikel
|
| 207 |
The prognostic and predictive role of the androgen receptor in TNBC treated with neo-adjuvant chemotherapy
|
Jongen, L.
|
|
|
30 |
S3 |
p. iii36-iii37
|
artikel
|
| 208 |
The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial
|
Lambertini, M.
|
|
|
30 |
S3 |
p. iii28
|
artikel
|
| 209 |
The spatial relations among immune cells are prognostic in inflammatory breast cancer
|
Van Berckelaer, C.
|
|
|
30 |
S3 |
p. iii11
|
artikel
|
| 210 |
TILs in ER+/HER2- breast cancer
|
Criscitiello, C.
|
|
|
30 |
S3 |
p. iii3
|
artikel
|
| 211 |
Translational Research Index
|
|
|
|
30 |
S3 |
p. iii75-iii76
|
artikel
|
| 212 |
Trastuzumab related cardiotoxicity in nonmetastatic breast cancer: A real-world scenario
|
Shrivastva, S.
|
|
|
30 |
S3 |
p. iii69
|
artikel
|
| 213 |
Treatment outcomes after post-operative radiotherapy in triple-negative breast cancer: Multi-institutional retrospective study (KROG 17-05)
|
Kim, J.H.
|
|
|
30 |
S3 |
p. iii40
|
artikel
|
| 214 |
Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome
|
Onesti, C.E.
|
|
|
30 |
S3 |
p. iii18
|
artikel
|
| 215 |
Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer
|
Smyth, L.M.
|
|
|
30 |
S3 |
p. iii10-iii11
|
artikel
|
| 216 |
Utility of early circulating tumour DNA dynamics as a surrogate for progression free survival in the BEECH phase I/II trial in metastatic breast cancer
|
Hrebien, S.
|
|
|
30 |
S3 |
p. iii3
|
artikel
|
| 217 |
Utilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER)
|
Mougalian, S.
|
|
|
30 |
S3 |
p. iii54
|
artikel
|
| 218 |
Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna
|
Tendl, K.A.
|
|
|
30 |
S3 |
p. iii9
|
artikel
|
| 219 |
Validating the CTS5 algorithm with the IDEAL study cohort
|
Noordhoek, I.
|
|
|
30 |
S3 |
p. iii29
|
artikel
|
| 220 |
Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial
|
Dieci, M.V.
|
|
|
30 |
S3 |
p. iii27-iii28
|
artikel
|
| 221 |
Variation in radiotherapy after breast conserving surgery in patients aged 75 years or older between hospitals is not reflected in the locoregional recurrence risk
|
de Boer, A.Z.
|
|
|
30 |
S3 |
p. iii39
|
artikel
|
| 222 |
WNT, Hedgehog and NOTCH signaling pathways in triple negative breast cancer with high and low content of cancer stem cells
|
Brilliant, A.
|
|
|
30 |
S3 |
p. iii13-iii14
|
artikel
|
Tijdschrift beschrijving